IBRX heads for worst week since July amid new Anktiva patent
ImmunityBio’s IBRX stock was down 4.2% to $7.72 on Thursday as investors weighed a newly published patent application outlining broader potential uses for Anktiva ahead of a major global lung-cancer conference.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.